Salvo, P.F.; Farinacci, D.; Ciccullo, A.; Borghi, V.; Rusconi, S.; Saracino, A.; Gennari, W.; Bruzzone, B.; Vicenti, I.; Callegaro, A.;
et al. Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype. Viruses 2023, 15, 762.
https://doi.org/10.3390/v15030762
AMA Style
Salvo PF, Farinacci D, Ciccullo A, Borghi V, Rusconi S, Saracino A, Gennari W, Bruzzone B, Vicenti I, Callegaro A,
et al. Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype. Viruses. 2023; 15(3):762.
https://doi.org/10.3390/v15030762
Chicago/Turabian Style
Salvo, Pierluigi Francesco, Damiano Farinacci, Arturo Ciccullo, Vanni Borghi, Stefano Rusconi, Annalisa Saracino, William Gennari, Bianca Bruzzone, Ilaria Vicenti, Annapaola Callegaro,
and et al. 2023. "Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype" Viruses 15, no. 3: 762.
https://doi.org/10.3390/v15030762
APA Style
Salvo, P. F., Farinacci, D., Ciccullo, A., Borghi, V., Rusconi, S., Saracino, A., Gennari, W., Bruzzone, B., Vicenti, I., Callegaro, A., Di Biagio, A., Zazzi, M., Di Giambenedetto, S., & Borghetti, A.
(2023). Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype. Viruses, 15(3), 762.
https://doi.org/10.3390/v15030762
